PT - JOURNAL ARTICLE AU - Shuichi Yano AU - Kazunari Tsuyuguchi AU - Katsuhiro Suzuki AU - Toumei Ogawa AU - Katsuo Yamada AU - Masaji Okada AU - Norimasa Ito TI - Clinical resuts of therapy for non-tuberculous myocardium <em>avium</em> complex -Multicentric retrospective study of 581 patients in Japan AID - 10.1183/13993003.congress-2015.PA2680 DP - 2015 Sep 01 TA - European Respiratory Journal PG - PA2680 VI - 46 IP - suppl 59 4099 - http://erj.ersjournals.com/content/46/suppl_59/PA2680.short 4100 - http://erj.ersjournals.com/content/46/suppl_59/PA2680.full SO - Eur Respir J2015 Sep 01; 46 AB - The clinical evidence of effect of medical treatment for Mycobacterium avium Complex patient is still limited.Methods Two handred sixty four patients in 16 facilities in Japan with primary therapy for Mycobacterium avium Complex lung disease with combination of Clarythromycin, Ethanbutol, Refanpicin, or other medicine was corrected retrospectively and analyzed its results. Microbiological culture results of sputum were analyzed as Primary endopoint.Results: The mean age was 65+/-12, 74 were male and 188 were female.197 patients had clinical symptons and 67 patients had no symptons. 30 patients had mixed infections. 192 patients were treated primarily with Clarythromycin, Refanpicin, and Ethanbutol (REC) +/- other antibiotics. Patients with symptons had less culture negative than with no symptons (50% vs 68%,p=0.0094), Patients with other pulmonary infectious disease had more culture positive (64% vs 54%, p=0.037). Patients treated with REC to the end had more culture negative (62% vs 49%, p=0.0041). 5 year survival rate was beter in culture negative petients than in culture positive patients (93.4% vs 77.8%)Conclusion: There is a possibility that REC might be a better regimen than others. We are still collecting retrospective cases up to 490 and we are now undergoing prospective study for analysing clinical results of REC treatment for patients with MAC lung desease.